drugs

Catalan pharmaceutical giant Grifols sees a 23% jump in net profit in the first half of 2014

July 31, 2014 09:29 PM | ACN / Neringa Sinkeviciute

During the first half of the year, the revenues of the Catalan multinational pharmaceutical company Grifols rose by 16.7% to €1.61 bilion, 75% of which came from the Bioscience division and 18% from Diagnostic. Compared to the first quarter, the proportion of total sales generated by each of the group’s divisions remains unchanged after the acquisition of Novartis' diagnostic business. The world´s third-largest blood-derivate product maker, Grifols obtained a net profit of €224.8 million, 23% more compared with the same period last year, as reported by the company to the Spanish Stock Exchange Authority (CNMV). These positive figures were achieved due to the maintenance of financial costs, made possible by improved financial conditions, despite having increased debt in absolute terms.

Catalonia, a hub of global biomedical research

July 25, 2014 12:32 PM | Bryony Clarke

Catalonia has established a reputation as a global centre of scientific excellence, pioneering research and innovative ideas. This corner of Europe, with just 0.1% of the world’s population, accounts for nearly 1% of global scientific production. The Catalan Research system, formed of 12 internationally esteemed universities, over 60 research centres, 15 world class hospitals, and almost 9,000 innovative companies, attests to the Catalonia's ambitions in science. This territory is also a magnet of international funding: with 1.5% of Europe’s population, it receives 2.2% of European competitive funds and 3.5% of European Research Council (ERC) grants. There can be no doubt that Catalonia is now a benchmark in Southern Europe, producing frontier research and punching considerably above its weight in terms of scientific contribution.  It is attracting worldwide talent and projects, and many consider it to be fast becoming the Palo Alto of biomedical research.

Catalan Oncology Institute will pay Roche drugs depending on clinical results

January 24, 2014 07:47 PM | ACN

The Catalan Institute of Oncology (ICO) and Roche pharmaceutical company have signed an agreement stating that the Catalan public institute will pay for treatments against cancer depending on clinical results adapted to each specific patient. For now, the agreement provides that Roche will supply two drugs against the most common cancers, mostly breast and colon. According to the agreement, the probabilities of success will be thoroughly examined and if they meet the requirements, the Catalan Government will fully pay for the treatment. If not, Roche will assume the costs progressively according to the degree of success.

Catalan Police’s largest-ever operation ends with 33 drug dealers arrested

November 15, 2013 09:18 PM | ACN / Lluís Vilaró

The extensive Catalan Police operation against drug trafficking in Barcelona’s Zona Franca quarter and in Sant Adrià de Besós’ (North of Barcelona) ‘La Mina’ neighbourhood resulted in 33 arrests and 29 homes searched. With 300 police officers deployed from 7 different police areas, this operation was the largest-ever made by the Catalan Government’s police corps in terms of officers deployed. Catalan Minister for Home Affairs, Ramon Espadaler, stated that further arrests could still be announced in the following days. The investigation leading to this operation had begun in December 2012.